Calculus invests in Trogenix
Calculus invests as part of a £70million Series A financing to drive clinical development of therapies for hard to treat cancers.
Calculus backs the innovators, the experts and the game changers across the fastest growing sectors in the UK – technology, healthcare and the creative industries.
We focus on companies driving innovation, advancing healthcare and creating jobs and opportunities throughout the country.
Calculus invests as part of a £70million Series A financing to drive clinical development of therapies for hard to treat cancers.
Arecor partners with Sequel Med Tech on AT278 insulin and raises up to $11m from Ligand, accelerating Phase 2 readiness, extending cash runway to 2027, and positioning for next-generation diabetes care and significant shareholder value creation.
Calculus portfolio company C4X Discovery selects a best-in-class oral IBD candidate, highlighting innovation and value creation in UK biotech.
Here we speak to Richard Moore, Co-Head of Investments, on the key lessons learned and how that informs our investment strategy in the technology space.